Metformin versus metformin plus pioglitazone on gonadal and metabolic profiles in normal-weight women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial

Han Zhao,Jiaqi Zhang,Chuan Xing,Xiangyi Cheng,Bing He
DOI: https://doi.org/10.1186/s13048-024-01367-7
2024-02-21
Journal of Ovarian Research
Abstract:To investigate the effects of metformin (MET) monotherapy and pioglitazone plus MET (PIOMET) therapy on gonadal and metabolic profiles in normal-weight women with polycystic ovary syndrome (PCOS).
reproductive biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the effects of metformin (MET) monotherapy and pioglitazone plus metformin (PIOMET) combination therapy on reproductive and metabolic characteristics in normal - weight women with polycystic ovary syndrome (PCOS). Specifically, the study aims to: 1. **Compare the effects of the two treatment methods on the menstrual cycle**: Evaluate the effects of MET monotherapy and PIOMET combination therapy in improving the menstrual cycle of normal - weight PCOS women. 2. **Evaluate the changes in sex hormone levels**: Analyze the effects of the two treatment methods on sex hormone levels such as luteinizing hormone (LH), follicle - stimulating hormone (FSH), total testosterone (TT), sex hormone - binding globulin (SHBG), free androgen index (FAI) and androstenedione (AND). 3. **Evaluate the changes in glucose metabolism**: Evaluate the effects of the two treatment methods on glucose metabolism parameters such as fasting plasma glucose (FPG), fasting insulin (FINS), insulin resistance index (HOMA - IR), area under the glucose curve (AUCGlu) and area under the insulin curve (AUCIns) through the oral glucose - insulin release test (OGIRT). The main purpose of the study is to explore whether PIOMET combination therapy is more effective than MET monotherapy in improving the reproductive and metabolic characteristics of normal - weight PCOS women.